6:11 PM
 | 
Mar 29, 2007
 |  BC Extra  |  Company News

FDA wants another cintredekin besudotox Phase III

NeoPharm (NEOL) fell $0.20 (11%) to $1.67 on Thursday after the company said FDA would require an additional Phase III trial of cintredekin besudotox to treat glioblastoma multiforme (GBM)...

Read the full 129 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >